

**LIONEL SÉGARD**Chairman & Chief  
Executive Officer

## Dear shareholders,

We are pleased to send you this first shareholder letter. We hope to make this communication tool a way of providing you with in-depth information on a regular basis to help you understand our strategy and how our projects are progressing.

After a structurally eventful 2015, we have entered 2016 focused on internationalizing and accelerating our development.

In the field of Heart Failure (HF), we announced our intention to begin Phase IIa human clinical trials this summer, 2016, more than six months earlier than originally planned.

At the same time, we opened an office in New York on March 1 with a view to our international development. In anticipation of our upcoming multicentric trials in the United States, a Clinical Advisory Board was formed there, consisting of eminent specialists who bring us their recognized expertise in setting up clinical trials for categories of patients, their knowledge of Food & Drug Administration (FDA) regulators and contacts with the community of North American clinicians. The first meeting of the U.S. Clinical Advisory Board was in March and launched the first bases of our upcoming Phase IIb trials for High Blood Pressure (HBP) on the other side of the Atlantic. In this newsletter, you will find a portrait of Dr. Keith C. Ferdinand, a member of this Clinical Advisory Board.

Being ahead of schedule has meant incurring in 2016 expenses that we had forecasted for 2017. We also chose to secure our financing by undertaking a capital increase in March 2016 totalling €8.6 million: €5.6 million via private placement with institutional funds in the United States and €3.0 million via a public offering.

This fundraising allows us to look on the future serenely, especially in light of the acceleration in our development programmes. All the more so as the total funds raised will be €14.1 million if all the warrants attached to the newly issued shares are exercised.

**2016 stands to be a year full of promise, with the international deployment of ambitious clinical trials.** We are thinking in particular of the launch of Phase IIa clinical trials for Heart Failure – a major pan-European study – as well as the completion of the Phase IIa clinical trials for High Blood Pressure. The road is now open to set up, in 2017, two new Phase IIb clinical trials for High Blood Pressure: one on a targeted population in the United States and the other in Europe with precise work on biomarkers.

On behalf of the entire team at Quantum Genomics, I wish to thank you for your trust and loyalty, and hope that you will find this first shareholder letter informative.

# QUANTUM GENOMICS SYMPOSIUM AT THE EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION



Quantum Genomics will be taking part in the 26th European Meeting on Hypertension and Cardiovascular Protection, from the 10th to the 13<sup>th</sup> of June 2016, organised by the ESH (*European Society of Hypertension*), which will be held this year in France, at the Palais des Congrès de Paris.

This event brings together opinion leaders, researchers, experts and cardiologists from all over the globe to present current research, best practices, recommendations, new technologies and new tools relating to Arterial Hypertension and Cardiovascular Protection.

For the first time, on the 12th of June, Quantum Genomics will be holding a symposium for nearly 400 participants, led by Pr. Pierre Corvol, President of the Scientific Committee, and Pr. Michel Azizi, Director of the Clinical Investigation Centre of the Hôpital Européen Georges Pompidou in Paris and investigator of the phase IIA clinical trial for drug candidate QGC001.

The mechanism of action and a synthesis of the promising results of QGC001 obtained in arterial hypertension will be presented by Dr. Catherine Llorens-Cortes, Director of the INSERM Unit which carried out the initial research into QGC001. Pr. Frans Leenen, of the University of Ottawa Heart Institute, will describe their current work into the use of QGC001 in heart failure and the new encouraging results obtained in animals for this indication. Pr. Stéphane Laurent, of Paris Descartes University, will highlight the importance of BAPAI in the current

therapeutic arsenal and their contribution towards currently unsatisfied medical needs.

At this event, a scientific presentation will also be led by Dr. Yannick Marc, researcher at Quantum Genomics, working within the joint laboratory CADIOBAPAI at the Collège de France.

The presence of Quantum Genomics at this congress, the most important international meeting in the field of Arterial Hypertension and Cardiovascular Diseases, will further enhance the visibility and reputation of QGC001 within the international scientific community.





## ZOOM ON THE UNITED STATES

The United States is a leading market for healthcare players, especially in the field of hypertension. This disorder affects more than 100 million Americans and is one of the main risk factors for heart disease. Quantum Genomics decided to cross the Atlantic, opening a first office in New York on March 1 this year.


As part of its development in the United States, and with a view to the upcoming multicentric clinical trials there, Quantum Genomics has also formed a U.S. Clinical Advisory Board consisting of Dr Keith C. Ferdinand (read below), Dr Henry Black and Dr Howard Dittrich, recognized clinicians in arterial hypertension and cardiology. The Committee held its first meeting on March 3 this year.

At the same time, Quantum Genomics has undertaken to strengthen its intellectual property to protect its leading drug candidate QGC001, in one of its key target markets. In this respect, the U.S. Patent and Trademark

Office recently granted two new patents in the United States, the first covering the crystalline trihydrate form of QGC001, and the second a new crystalline form of QGC001 associated with L-lysine, and their use in the treatment of High Blood Pressure and Heart Failure. These patents consolidate the protection of QGC001 and its use in both these indications, potentially until 2038.

Lastly, the equity stake taken in our company by the U.S. investment fund Sabby Management, a recognized biotechnology specialist, confirms the pertinence of Quantum Genomics' positioning and demonstrates the interest in its therapeutic innovation beyond our own borders.

With all these stages now completed, Quantum Genomics is looking forward to working with Food and Drug Administration (FDA) regulators this year with a view to conducting Phase IIb clinical trials in 2107 for High Blood Pressure in a targeted population.



### PORTRAIT OF DOCTOR KEITH C. FERDINAND

Member of  
Quantum Genomics'  
American Clinical  
Ethics Committee

**Dr Keith C. Ferdinand, M.D.**, is Professor of Medicine in the Faculty of Medicine at Tulane University in New Orleans, Louisiana.

He graduated in internal medicine and cardiovascular diseases, holds a speciality in nuclear cardiology, and is certified by the American Society of Hypertension (ASH) as a specialist in the field of clinical hypertension.

Dr Ferdinand is the former President of the National Forum for Heart Disease & Stroke Prevention. As a researcher, Dr Ferdinand has led number trials and published numerous articles in the field of cardiology and heart disease, hypertension, lipids and cardiometabolic risk, particularly among racial and ethnic

minorities. In 2015, he edited a book entitled "Hypertension in High Risk African Americans", published by Springer.

In 2004, Dr Ferdinand received the American Heart Foundation's Louis B. Russell Prize, and in 2010 the Walter M. Booker Community Service Prize from the Association of Black Cardiologists, of which he was Chairman and Chief Science Officer. He was awarded a prize for journalism by the Congressional Black Caucus Health Trust, and received the Charles Drew Award for Medical Excellence in collaboration with the National Minority Quality Foundation. In 2015, Dr Ferdinand was inducted into the Association of University Cardiologists.



# SHAREHOLDER GUIDE

## Stock market data

31 mai 2016

Share price on 31 May 2016  
**6.02 euros**

Number of shares: **8,390,320**

Market capitalisation: **50.5 million euros**

**63.0%**

Float

**14.6%**


Alix AM

**11.8%**

Téthys

**10.6%**

Management



## Stock information

Market: Alternext Paris  
Ticker: ALQGC  
ISIN Code: FR0011648971  
Reuters Code: ALQGC.PA  
Bloomberg Code : ALQGC:FP

## FINANCIAL CALENDAR

15 June 2016	General Meeting of Shareholders
13 October 2016	Half-year results 2016

## INVESTOR MEETINGS

5 & 6 June 2016	French Life Sciences Days (San Francisco, États-Unis)
11 & 13 September 2016	Rodman & Renshaw Global Investment Conference (New York, États-Unis)
22 September 2016	Individual Investors meeting organised by F2iC federation (Paris, France)
5 & 6 October 2016	European Large & Midcap Event (Paris, France)
18 & 19 November 2016	Actionaria - individual investors trade fair (Paris, France)

## INTERNATIONAL EVENTS

6-9 June 2016	BIO International Convention (San Francisco, United States)
12 June 2016	Symposium Quantum Genomics on the occasion of the 26 <sup>th</sup> ESH Congress (European Meeting on Hypertension and Cardiovascular Protection) in Paris

## Press Reviews

**Le Revenu, 13 May 2016:** «Quantum Genomics researchers are not the first to be interested in hypertension. But their approach, which consists of acting on the neurological mechanisms triggering this disease, is novel.»

**Boursier.com, 26 April 2016:** «Quantum Genomics to begin Phase IIa for the treatment of heart failure.»

**Reuters, 26 April 2016 :** « Quantum Genomics receives authorisation to begin Phase IIA multicentric European trial.»

**Le Figaro, 15 March 2016:** « Quantum Genomics, a biotech specializing in the development of new therapies in the cardiovascular field, announced Tuesday it had raised 5.54 million euros in the United States.»



## Contact us

**Lionel Ségard**  
Chairman & CEO

**Marc Karako**  
Chief Financial Officer – Investor Relations

Tour Maine Montparnasse - 33 avenue du Maine - 75015 Paris  
Tel: +33 1 85 34 77 70 - Email : [contact@quantum-genomics.com](mailto:contact@quantum-genomics.com)